Nina P Paynter

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8796973/publications.pdf

Version: 2024-02-01

34 papers	2,781 citations	430754 18 h-index	414303 32 g-index
34 all docs	34 docs citations	34 times ranked	5224 citing authors

#	Article	IF	Citations
1	Abstract P021: Performance Of Pooled Cohort Equations And MESA Risk Score Across Race/Ethnicity And Socioeconomic Status To Estimate 10-year Cardiovascular Risk In Diverse New England Cohort. Circulation, 2022, 145, .	1.6	4
2	Adverse effects related to methotrexate polyglutamate levels: adjudicated results from the cardiovascular inflammation reduction trial. Rheumatology, 2021, 60, 2963-2968.	0.9	3
3	Metabolomic profiles associated with all-cause mortality in the Womenâ€™s Health Initiative. International Journal of Epidemiology, 2020, 49, 289-300.	0.9	20
4	Adverse Effects of Lowâ€Dose Methotrexate in a Randomized Doubleâ€Blind Placeboâ€Controlled Trial: Adjudicated Hematologic and Skin Cancer Outcomes in the Cardiovascular Inflammation Reduction Trial. ACR Open Rheumatology, 2020, 2, 697-704.	0.9	18
5	Adverse Effects of Low-Dose Methotrexate. Annals of Internal Medicine, 2020, 172, 369.	2.0	126
6	Metabolomic Effects of Hormone Therapy and Associations With Coronary Heart Disease Among Postmenopausal Women. Circulation Genomic and Precision Medicine, 2020, 13, e002977.	1.6	4
7	External Validation of a Risk Score for Major Toxicity Among Nonsteroidal Antiâ€Inflammatory Drug Users: Realâ€World Application. ACR Open Rheumatology, 2020, 2, 269-275.	0.9	0
8	Metabolic signatures associated with Western and Prudent dietary patterns in women. American Journal of Clinical Nutrition, 2020, 112, 268-283.	2.2	18
9	Derivation and Validation of a Major Toxicity Risk Score Among Nonsteroidal Antiinflammatory Drug Users Based on Data From a Randomized Controlled Trial. Arthritis and Rheumatology, 2019, 71, 1225-1231.	2.9	11
10	Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. New England Journal of Medicine, 2019, 380, 752-762.	13.9	886
11	Estimating the receiver operating characteristic curve in matched case control studies. Statistics in Medicine, 2019, 38, 437-451.	0.8	8
12	Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. American Heart Journal, 2018, 206, 80-93.	1.2	276
13	Reclassification calibration test for censored survival data: performance and comparison to goodness-of-fit criteria. Diagnostic and Prognostic Research, 2018, 2, .	0.8	5
14	Evaluation of the Pooled Cohort Risk Equations for Cardiovascular Risk Prediction in a Multiethnic Cohort From the Womenâ€™s Health Initiative. JAMA Internal Medicine, 2018, 178, 1231.	2.6	58
15	Investigating methotrexate toxicity within a randomized double-blinded, placebo-controlled trial: Rationale and design of the Cardiovascular Inflammation Reduction Trial-Adverse Events (CIRT-AE) Study. Seminars in Arthritis and Rheumatism, 2017, 47, 133-142.	1.6	26
16	Primary Prevention With Statin Therapy in the Elderly. Circulation, 2017, 135, 1979-1981.	1.6	97
17	Cardiovascular Risk Prediction. Circulation Research, 2017, 121, 1032-1033.	2.0	0
18	Clinical risk reclassification at 10Âyears. Statistics in Medicine, 2017, 36, 4498-4502.	0.8	10

#	Article	IF	Citations
19	Adding tests to risk based guidelines: evaluating improvements in prediction for an intermediate risk group. BMJ, The, 2016, 354, i4450.	3.0	6
20	Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus. JAMA Cardiology, 2016, 1, 136.	3.0	53
21	Relation of Alanine Aminotransferase Levels to Cardiovascular Events and Statin Efficacy. American Journal of Cardiology, 2016, 118, 49-55.	0.7	5
22	Are Genetic Tests for Atherosclerosis Ready for Routine Clinical Use?. Circulation Research, 2016, 118, 607-619.	2.0	28
23	Complete blood count risk score and its components, including RDW, are associated with mortality in the JUPITER trial. European Journal of Preventive Cardiology, 2015, 22, 519-526.	0.8	41
24	Genome-wide meta-analysis identifies six novel loci associated with habitual coffee consumption. Molecular Psychiatry, 2015, 20, 647-656.	4.1	235
25	Cardiovascular Disease Risk Prediction in Women: Is There a Role for Novel Biomarkers?. Clinical Chemistry, 2014, 60, 88-97.	1.5	19
26	A Bias-Corrected Net Reclassification Improvement for Clinical Subgroups. Medical Decision Making, 2013, 33, 154-162.	1.2	34
27	Comments on â€˜Extensions of net reclassification improvement calculations to measure usefulness of new biomarkersâ€™ by M. J. Pencina, R. B. D'Agostino, Sr. and E. W. Steyerberg. Statistics in Medicine, 2012, 31, 93-95.	0.8	20
28	Does the 9p21 Genetic Variant Have a Role in Cardiovascular Risk Prediction?. Current Cardiovascular Risk Reports, 2011, 5, 159-164.	0.8	1
29	Performance of reclassification statistics in comparing risk prediction models. Biometrical Journal, 2011, 53, 237-258.	0.6	97
30	Lipoprotein Subclass Abnormalities and Incident Hypertension in Initially Healthy Women. Clinical Chemistry, 2011, 57, 1178-1187.	1.5	42
31	Cardiovascular Risk Prediction in Diabetic Men and Women Using Hemoglobin A_{1c} vs Diabetes as a High-Risk Equivalent. Archives of Internal Medicine, 2011, 171, 1712.	4.3	33
32	Association Between a Literature-Based Genetic Risk Score and Cardiovascular Events in Women. JAMA - Journal of the American Medical Association, 2010, 303, 631.	3.8	320
33	Prediction of Incident Hypertension Risk in Women with Currently Normal Blood Pressure. American Journal of Medicine, 2009, 122, 464-471.	0.6	52
34	Cardiovascular Disease Risk Prediction With and Without Knowledge of Genetic Variation at Chromosome 9p21.3. Annals of Internal Medicine, 2009, 150, 65.	2.0	225